文献速递肿瘤 PET/CT

多变量[68Ga]Ga-PSMA-11 PET预测模型用于中高危前列腺癌淋巴结受累的开发与外部验证

Development and external validation of a multivariable [68Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-06-01

回顾性纳入两个三级转诊中心接受[68Ga]Ga-PSMA-11 PET、扩大盆腔淋巴结清扫和根治性前列腺切除术的中高危前列腺癌患者,训练队列173例(2013–2017年),验证队列90例(2016–2019年)。包含前列腺特异性抗原、活检Gleason分级分组、原发肿瘤[68Ga]Ga-PSMA-11阳性体积和[68Ga]Ga-PSMA-11报告N状态的联合模型外部验证AUC为0.923(95%CI 0.863–0.984)。以≥17%为切点,可避免44例(50%)扩大盆腔淋巴结清扫,漏诊淋巴结侵犯1例(4.8%)。

要点

  • 联合模型外部验证AUC为0.923(95%CI 0.863–0.984)。
  • 以≥17%为切点,可避免44例(50%)扩大盆腔淋巴结清扫,漏诊淋巴结侵犯1例(4.8%)。
  • 作者认为[68Ga]Ga-PSMA-11信息可能改善中高危前列腺癌患者初次分期时的淋巴结侵犯预测,尤其是与临床参数联合时。

核心结论

  • 作者认为[68Ga]Ga-PSMA-11信息可能改善接受初次分期中高危前列腺癌患者的淋巴结侵犯预测,尤其是与临床参数联合时。
  • 作者提出未来研究应探讨联合PSMA PET与mpMRI信息用于根治性前列腺切除术前前列腺癌患者的淋巴结侵犯预测。

研究设计与样本

  • 回顾性识别两个三级转诊中心连续接受[68Ga]Ga-PSMA-11 PET、扩大盆腔淋巴结清扫和根治性前列腺切除术的中高危前列腺癌患者。
  • 训练队列173例(2013–2017年治疗),验证队列90例(2016–2019年治疗)。
  • 开发并采用交叉验证评估三个淋巴结侵犯预测模型,在模型开发过程中确定最佳风险阈值。

主要发现

  • 联合模型外部验证AUC为0.923(95%CI 0.863–0.984)。
  • 以≥17%为切点,可避免44例(50%)扩大盆腔淋巴结清扫,漏诊淋巴结侵犯1例(4.8%)。
  • 与传统模型和基于MRI的模型相比,所提模型校准相似,AUC更高(0.923(95%CI 0.863–0.984) vs. 0.700(95%CI 0.548–0.852)–0.824(95%CI 0.710–0.938)),决策曲线分析净获益更高。

关键数值与推荐

  • 联合模型包含前列腺特异性抗原、活检Gleason分级分组、原发肿瘤[68Ga]Ga-PSMA-11阳性体积和[68Ga]Ga-PSMA-11报告N状态评估。
  • 最佳风险切点为≥17%,该切点下可避免44例(50%)扩大盆腔淋巴结清扫,漏诊淋巴结侵犯1例(4.8%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop and evaluate a lymph node invasion (LNI) prediction model for men staged with [68Ga]Ga-PSMA-11 PET. METHODS: A consecutive sample of intermediate to high-risk prostate cancer (PCa) patients undergoing [68Ga]Ga-PSMA-11 PET, extended pelvic lymph node dissection (ePLND), and radical prostatectomy (RP) at two tertiary referral centers were retrospectively identified. The training cohort comprised 173 patients (treated between 2013 and 2017), the validation cohort 90 patients (treated between 2016 and 2019). Three models for LNI prediction were developed and evaluated using cross-validation. Optimal risk-threshold was determined during model development. The best performing model was evaluated and compared to available conventional and multiparametric magnetic resonance imaging (mpMRI)-based prediction models using area under the receiver operating characteristic curves (AUC), calibration plots, and decision curve analysis (DCA). RESULTS: A combined model including prostate-specific antigen, biopsy Gleason grade group, [68Ga]Ga Ga-PSMA-11 positive volume of the primary tumor, and the assessment of the [68Ga]Ga-PSMA-11 report N-status yielded an AUC of 0.923 (95% CI 0.863-0.984) in the external validation. Using a cutoff of ≥ 17%, 44 (50%) ePLNDs would be spared and LNI missed in one patient (4.8%). Compared to conventional and MRI-based models, the proposed model showed similar calibration, higher AUC (0.923 (95% CI 0.863-0.984) vs. 0.700 (95% CI 0.548-0.852)-0.824 (95% CI 0.710-0.938)) and higher net benefit at DCA. CONCLUSIONS: Our results indicate that information from [68Ga]Ga-PSMA-11 may improve LNI prediction in intermediate to high-risk PCa patients undergoing primary staging especially when combined with clinical parameters. For better LNI prediction, future research should investigate the combination of information from both PSMA PET and mpMRI for LNI prediction in PCa patients before RP.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Muehlematter UJ, Schweiger L, Ferraro DA, et al. Development and external validation of a multivariable [68Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2023. PMID: 37261472. doi:10.1007/s00259-023-06278-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。